SCHEMBL901739

SCHEMBL901739

CC(C)(C)OC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(=O)OCc1ccccc1-c1ccc2nc(N)nc(C(=O)N3Cc4ccccc4C3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 8/20 0.56
TDP1 Q9NUW8 1/20 0.46
HSP90AB1 P08238 3/20 0.44
KLK7 P49862 1/20 0.39
KLK5 Q9Y337 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGA2B P08514 1/20 0.39
TLR2 O60603 1/20 0.38
TLR1 Q15399 1/20 0.38
CXCR3 P49682 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL901461 0.93 HSP90AA1 (0.47) HSP90AA1TDP1HSP90AB1KLK7KLK5
SCHEMBL902209 0.92 HSP90AA1 (0.54) HSP90AA1TDP1HSP90AB1KLK7KLK5
SCHEMBL17416333 0.91 HSP90AA1 (0.54) HSP90AA1TDP1HSP90AB1KLK7KLK5
SCHEMBL15099531 0.90 HSP90AA1 (0.47) HSP90AA1TDP1HSP90AB1KLK7KLK5
SCHEMBL901465 0.89 HSP90AA1 (0.59) HSP90AA1TDP1HSP90AB1KLK7KLK5
SCHEMBL901501 0.84 HSP90AA1 (0.53) HSP90AA1TDP1HSP90AB1CXCR3
SCHEMBL901504 0.82 HSP90AA1 (0.63) HSP90AA1HSP90AB1
SCHEMBL902136 0.82 HSP90AA1 (0.50) HSP90AA1HSP90AB1
SCHEMBL901819 0.81 HSP90AA1 (0.57) HSP90AA1TDP1HSP90AB1
SCHEMBL902122 0.81 HSP90AA1 (0.55) HSP90AA1TDP1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 US claimed
EP-2621919-A1 PHENYLQUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2013-08-07 EP claimed
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-07-11 US claimed
WO-2012041435-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-04-05 WO claimed
US-8791129-B2 Phenylquinazoline derivatives MERCK PATENT GMBH (DE) 2014-07-29 US disclosed
EP-2621919-A1 PHENYLQUINAZOLINE DERIVATIVES Merck Patent GmbH (DE) 2013-08-07 EP disclosed
WO-2012041435-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-04-05 WO disclosed
WO-2012041435-A1 PHENYLQUINAZOLINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130178443-A1 PHENYLQUINAZOLINE DERIVATIVES HSP90B1, HSP90AB1, HSP90AA1 HSP90AA1 3/4885TDP1 446/4885HSP90AB1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.